Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure

Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new head of corporate affairs, a move aimed at strengthening its political and public relations strategy as President Donald Trump intensifies pressure on drug pricing. Miley, formerly senior vice president of government affairs at AbbVie, announced his new role on LinkedIn, while Novo Nordisk confirmed the appointment through Reuters. He will assume his position next month and relocate to Denmark, the company’s headquarters.

This leadership change comes as CEO Mike Doustdar works to restore investor confidence through a sweeping restructuring that includes cutting 9,000 jobs globally—5,000 of which are in Denmark—and layoffs across multiple U.S. divisions. Novo faces fierce competition from U.S. rival Eli Lilly in the fast-growing obesity drug market, where its blockbuster drugs Wegovy and Ozempic have dominated headlines.

Industry insiders say Miley’s top priority will be managing relations with the Trump administration, a critical task given the administration’s scrutiny of drug pricing. The company’s current U.S. public affairs lead, Jennifer Duck, has a background rooted in Democratic politics, which sources say may not align well with the current Republican-led administration. By appointing an executive with deep Republican ties and two decades of pharmaceutical experience, Novo aims to navigate the complex political and regulatory landscape in its largest market.

Trump’s recent remarks about lowering the price of Novo’s diabetes treatment Ozempic sent shares of both Novo and Eli Lilly down on Friday. With over 20 years in pharma—including roles at Abbott and Pfizer—Miley’s appointment signals Novo’s commitment to reinforcing its U.S. strategy amid intensifying political and market challenges.